Skip to Content
Merck
All Photos(1)

Key Documents

SAB4501221

Sigma-Aldrich

Anti-HTRA2 antibody produced in rabbit

affinity isolated antibody

Synonym(s):

OMI®, Omi stress-regulated endoprotease, PRSS25, high temperature requirement protein A2, serine protease 25

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen 48 kDa

species reactivity

human, mouse, rat

concentration

~1 mg/mL

technique(s)

ELISA: 1:40000
immunohistochemistry: 1:50-1:100

NCBI accession no.

O43464

UniProt accession no.

O43464

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... HTRA2(27429)

General description

Anti-HTRA2 Antibody detects endogenous levels of total HTRA2 protein.

Immunogen

The antiserum was produced against synthesized peptide derived from human HtrA2.

Immunogen Range: 181-230

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Legal Information

OMI is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xi Gu et al.
Genome biology, 22(1), 86-86 (2021-03-24)
Aging, noise, infection, and ototoxic drugs are the major causes of human acquired sensorineural hearing loss, but treatment options are limited. CRISPR/Cas9 technology has tremendous potential to become a new therapeutic modality for acquired non-inherited sensorineural hearing loss. Here, we

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service